
Edited by Jean-Marc Cavaillon and Mervyn Singer

Inflammation

From Molecular and Cellular Mechanisms to the Clinic



WILEY-VCH

The leading reference on this topic of increasing medical relevance is unique in offering unparalleled coverage.

The editors are among the most respected researchers in inflammation worldwide and here have put together a prestigious team of contributors. Starting with the molecular basis of inflammation, from cytokines via the innate immune system to the different kinds of inflammatory cells, they continue with the function of inflammation in infectious disease before devoting a large section to the relationship between inflammation and chronic diseases. The book concludes with wound and tissue healing and options for therapeutic interventions. A must have for clinicians and biomedical researchers alike.



Jean-Marc Cavaillon is professor and was Head of the Unit "Cytokines and Inflammation" at Institut Pasteur (Paris). He has been President (1998-2000) of the "International Endotoxin and Innate Immunity Society", and President of the "European Shock Society" (2016-2017). He is member of the Editorial Boards of few journals including Shock, Journal of Infectious Diseases, and International Journal of Inflammation, and has been Associate-Editor of "Cytokine" (2002-2009). He has an extensive expertise in inflammation, innate immunity, particularly on cytokines, bacterial endotoxins and other Toll-like receptors agonists, endotoxin tolerance, activation of monocytes/macrophages and neutrophils.

He made major studies deciphering the altered immune status in sepsis and SIRS patients, and contributed to define the reprogramming of circulating leukocytes of these patients. He is the author of a book in French on Cytokines (Masson, 1993 & 1996), and the co-author of a book "Sepsis and non-infectious inflammation: from biology to critical care" (Wiley VCH, 2009).



Mervyn Singer is Professor of Intensive Care Medicine at University College London. His primary research interests are sepsis and multiorgan failure, infection, shock and haemodynamic monitoring. Funding for these activities primarily comes from the Wellcome Trust, Medical Research Council and National Institute for Health Research.

He developed an oesophageal Doppler haemodynamic monitor that is now in widespread use worldwide, the use of which has been shown in multiple studies to improve outcomes after major surgery and reduce length of stay. He has led on a number of important multi-centre trials in critical care. He has authored various papers and textbooks including the Oxford Handbook of Critical Care, now in its 3rd Edition, and is a Council member of the International Sepsis Forum. He was the first UK intensivist to be awarded Senior Investigator status by the National Institute for Health Research, and to be invited to give plenary lectures at the European and US Intensive Care Congresses.

Volume 3 of 4

ISBN 978-3-527-33899-3



Cavaillon • Singer (Eds.)

3

Inflammation

WILEY -VCH

Inflammation

From Molecular and Cellular Mechanisms to the Clinic

Edited by Jean-Marc Cavaillon and Mervyn Singer



Editors

Professor Dr. Jean-Marc Cavaillon Institut Pasteur Unit Cytokines & Inflammation rue Dr. Roux 28 75015 Paris France

Professor Dr. Mervyn Singer
University College London
Bloomsbury Institute of Intensive
Care Medicine
Cruciform Building
Gower St
WC1E 6BT London
United Kingdom

All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication DataA catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at http://dnb.d-nb.de.

© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Boschstr. 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form — by photoprinting, microfilm, or any other means — nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Print ISBN: 978-3-527-33899-3 ePDF ISBN: 978-3-527-69218-7 ePub ISBN: 978-3-527-69216-3 Mobi ISBN: 978-3-527-69217-0 oBook ISBN: 978-3-527-69215-6

Typesetting Thomson Digital, Noida, India

Printing and Binding C.O.S. Printers Pte Ltd Singapore

Printed on acid-free paper

10 9 8 7 6 5 4 3 2 1

Edited by Jean-Marc Cavaillon and Mervyn Singer

Inflammation

| Į |
|-----|
| |
| Ĭ |
| X |
| 7 |
| (2) |
| |
| Ď |
| |
| |
| Xk |
| |
| |
| |
| () |
| 1 |
| |
| () |
| |
| A |
| |

Preface

Inflammation is older than humanity itself. Indeed, the earliest signs of inflammatory processes can be found on the bones of dinosaurs. Inflammation has always been integral to humans as the key process that protects against sterile or infectious insults. By the end of the eighteenth century, John Hunter was among the first to define inflammation as a salutary function, a concept endorsed 100 years later by Elie Metchnikoff. To limit the side effects of inflammation, the use of herbal anti-inflammatory was introduced in China (2800 BC) and Egypt (1520 BC), well before Hippocrates. Bloodletting was another therapeutic approach widely supported for some 2000 years. While natural products remain an important source of new anti-inflammatory drugs, bloodletting has been recognized to be powerless!

Nowadays, the beneficial effects of inflammation are well recognized when associated with the overlapping innate immune response. In recent years, molecular and cellular players have been well characterized and their precise interactions better understood. New molecular mechanisms have been deciphered such as the inflammasome and epigenetics. However, the word inflammation remains mainly associated with disease. Indeed, many chronic inflammatory disorders have been identified as severe debilitating diseases that may even favor the emergence of certain cancers. Deciphering the molecular and cellular events underlying inflammation has enabled development of new drugs that have revolutionized treatment and outcomes of some of these disorders.

Major achievements have been made in the last few decades allowing new understanding of the cross-talk between immune and nonimmune cells (e.g., cytokines, neuromediators, and eicosanoids) and in the resolution of inflammation (e.g., control by the neuronal system, new lipid mediators). Well-recognized

xxiv | Preface

leaders in the field have contributed their specific expertise to this book, thus making it most comprehensive overview of inflammatory processes and associated diseases.

Institut Pasteur

Jean-Marc Cavaillon

Paris

France

University College London

Mervyn Singer

London, UK

1

Table of Contents

| Preface | e xxiii | |
|--|--|--|
| Volume I | | |
| 1 | Inflammation through the Ages: A Historical Perspective Jean-Marc Cavaillon | |
| Part One Inducers and Sensors of Inflammation 17 | | |
| 2 | Pathogen-associated Molecular Patterns 19 Jean-Marc Cavaillon | |
| 3 | Damage-associated Molecular Patterns 57 Jean-Marc Cavaillon | |
| 4 | Bacterial Toxins 81 Marina de Bernard and Cesare Montecucco | |
| 5 | Venoms 99 Catarina Teixeira, Vanessa Moreira, and José María Gutiérrez | |
| 6 | Hypoxia as an Inducer of Inflammation 129 Ariel Brandwein and Clifford S. Deutschman | |
| 7 | Vaccine Adjuvants 143 Dennis M. Klinman and Hidekazu Shirota | |

Pattern Recognition Receptors 175

Lauren Whitehead and Gordon D. Brown

8

| Part Two Inflammatory Cells 21 | Part | Two | Inflammatory | Cells | 21 |
|--------------------------------|------|-----|--------------|-------|----|
|--------------------------------|------|-----|--------------|-------|----|

- 9 Monocytes and Macrophages 219 Irina N. Shalova, Shilpi Saha, and Subhra K. Biswas
- 10 Neutrophils 253 Salvatore Cuzzocrea
- Mast Cells: Master Drivers of Immune Responses against 11 Pathogens 273 W.X. Gladys Ang and Soman N. Abraham
- 12 Dendritic Cells in Inflammatory Disease 289 Bart N. Lambrecht, Martin Guilliams, and Hamida Hammad
- Roles for NK Cells and ILC1 in Inflammation and Infection 315 13 Christian A.J. Vosshenrich and James P. Di Santo
- Group 2 and 3 Innate Lymphoid Cells: New Actors in Immunity 14 and Inflammation 341Nicolas Serafini and James P. Di Santo
- Th9 Cells: From the Bench to the Bedside and Back Again 15 Benjamin J. Ulrich, Matthew M. Hufford, and Mark H. Kaplan
- 16 **Th17 Cells** 395 Mélissa Noack and Pierre Miossec
- 17 Platelets 419 Jack Levin
- 18 Epithelial Cells 437 Jill M. Hoffman and Charalabos Pothoulakis
- Inflammation: The Role of Endothelial Cells 457 19 J. Steven Alexander, D. Neil Granger, and Norman R. Harris

Volume II

Part Three Inflammatory Mediators 477

- IL-1 Superfamily and Inflammasome 479 20 Charles A. Dinarello
- TNF Superfamily 529 21 Salvatore Cuzzocrea

| 22 | Interleukin-17 A-E 549 Giovanni Monteleone, Irene Marafini, and Edoardo Troncone | | |
|---------|--|--|--|
| 23 | IL-6 Superfamily 573 Toshio Tanaka, Masashi Narazaki, and Tadamistu Kishimoto | | |
| 24 | Type I and II Cytokine Superfamilies in Inflammatory Responses 587 William F. Carson IV and Steven L. Kunkel | | |
| 25 | Chemokines and Chemotaxis 619 Osamu Yoshie and Kouji Matsushima | | |
| 26 | Lipid Mediators in Inflammation 651 Shuh Narumiya, Takehiko Yokomizo, and Junken Aoki | | |
| 27 | Free Radicals in Inflammation 695 Andrew Cumpstey and Martin Feelisch | | |
| 28 | Proteases 727 Celine Deraison, Chrystelle Bonnart, and Nathalie Vergnolle | | |
| 29 | Psychiatric Disorders and Inflammation 767 Robert Dantzer | | |
| 30 | Complement System 785 Peter A. Ward and Claudia Kemper | | |
| 31 | Heat Shock Proteins 813 Willem van Eden, Femke Broere, and Ruurd van der Zee | | |
| Volume | e III | | |
| Part Fo | our Inflammation and Host Response 831 | | |
| 32 | Inflammation and Coagulation 833 Marcel Levi | | |
| 32.1 | Introduction 833 | | |
| 32.2 | Incidence of Inflammation-associated Coagulopathy 833 | | |
| 32.3 | Clinical Relevance of the Interaction between Inflammation and | | |
| | Coagulation 834 | | |
| 32.4 | Pathogenetic Pathways in the Coagulopathy of Sepsis 835 | | |
| | 32.4.1 Initiation of Inflammation-induced Activation of Coagulation 835 | | |
| | 32.4.2 Role of Platelets in Inflammation-induced Coagulation 836 | | |
| | 32.4.3 Downregulation of Physiological Anticoagulant and | | |
| | Fibrinolytic Pathways during Inflammation 837 | | |

| | 32.4.4 32.4.5 | Antithrombin and Inflammation 837 Activated Protein C and Inflammation 838 |
|---------|------------------|--|
| | 32.4.6 | Thrombomodulin and Inflammation 840 |
| | 32.4.7 | TFPI and Inflammation 841 |
| 32.5 | | tion of Inflammation by Coagulation in vivo 841 |
| | 32.5.1 | Extracellular DNA, Histones, and Neutrophil Extracellular |
| | | Traps 842 |
| 32.6 | Injured | Endothelium and Microparticles 843 |
| 32.7 | Systemi | c versus Localized Responses 843 |
| 32.8 | Organ-s | specific Responses by Endothelial Cells 844 |
| 32.9 | | stic Approach to the Inflammation-induced |
| 32.10 | | pathy 845 |
| 32.10 | | ive Treatment of Coagulation Abnormalities during Severe nation 847 |
| Refere | nces 84 | |
| Referen | 11003 01 | |
| 33 | Fever: N | 1ediators and Mechanisms 861 |
| | Joachim | |
| 33.1 | Introdu | |
| 33.2 | | hysiological and Neuroanatomical Considerations 862 |
| | | Fever Defined 862 |
| | 33.2.2 | Possible Sites of Action for Putative Pyrogens within the |
| | 22.2.2 | Neuronal Thermoregulatory Circuitries 864 |
| 22.2 | 33.2.3 | Experimentally Induced Fever 866 |
| 33.3 | | Peripherally Generated Endogenous Pyrogens 868 |
| | 33.3.1 | The Classical Pyrogenic Cytokines: TNF- α , IL-1 β , and IL-6 868 |
| | 33.3.2 | Putative Peripheral Triggers for the Early Phase of |
| | | Experimental Fever: PGE2, Complement Fragment C5a, or |
| | | Oxygen Radicals 869 |
| 33.4 | Transfe | r of Fever-generating Signals Across the Blood–Brain |
| | Barrier | 870 |
| | 33.4.1 | Sensory Circumventricular Organs (Cvos) 871 |
| | 33.4.2 | Cells Forming the Blood–Brain Barrier 871 |
| | 33.4.3 | A Rapid Signal Transfer from the Periphery to the Brain via |
| | | Sensory Nerves 873 |
| | | 33.4.3.1 The Afferent Vagus 873 |
| | | 33.4.3.2 Afferent Neuronal Signals from Other Nerves 873 |
| 33.5 | | y Acting Pyrogenic Mediators and Processing of Febrile Signals |
| | in the B | |
| | 33.5.1 | The Role of PGE2 in the MnPO 874 |
| | 33.5.2 | The Role of Noradrenaline in the POA 874 |
| | 33.5.3 | Other Centrally Acting Endogenous Pyrogens (Cytokines, |
| 22.6 | Cl: : 1 | Chemokines, and Other Substances) 875 |
| 33.6 | | Aspects of Fever 875 |
| | 33.6.1 | Is Fever Beneficial or Harmful? Some Classical |
| | | Arguments 876 |

Is Fever Beneficial or Harmful? No Clear Response from Clinical Studies 877 33.7 Concluding Remarks List of Abbreviations 878 References 879 Pain 891 Christoph Stein 34.1 Introduction 891 34.2 Basic Concepts of Pain 891 **Excitatory Mechanisms** 34.2.1 892 Inhibitory Mechanisms 895 34.2.2 34.2.2.1 Opioid Receptors and Signaling 896 34.2.2.2 Plasticity of Opioid Receptors and Signaling Pathways 896 34.2.2.3 Endogenous Opioid Receptor Ligands Clinical Concepts of Pain 899 34.3 Biopsychosocial Concept and Multidisciplinary 34.3.1 Management 900 34.3.2 **Analgesic Drugs** 900 34.3.2.1 Opioids 901 34.3.3 Translation of Basic Research into Clinical Applications 902 Conclusions and Outlook 34.4 903 Acknowledgments 904 References 904 Inflammation, Hormones, and Metabolism 915 Muska Khpal and Mervyn Singer 35.1 Introduction 915 35.2 Thyroid Hormones 915 35.2.1 Macrophages 916 Neutrophils 916 35.2.2 Natural Killer Cells 35.2.3 916 35.2.4 Lymphocytes 916 35.3 Steroid Hormones 917 Macrophages 917 35.3.1 Neutrophils 918 35.3.2 35.3.3 NK Cells 918 35.3.4 Lymphocytes 918 35.4 Sex Hormones 918 Macrophages 35.4.1 919 Neutrophils 35.4.2 919 35.4.3 NK Cells 919

34

35

35.4.4

35.5.1

35.5

Lymphocytes 919

Arginine Vasopressin

35.5.1.1 Macrophages

920

920

Pituitary Hormones 920

| | | 35.5.1.2 Lymphocytes 920 |
|-------|---------|---|
| | | 35.5.1.3 NK Cells 920 |
| | 35.5.2 | Prolactin 921 |
| | | 35.5.2.1 Macrophages 921 |
| | | 35.5.2.2 Neutrophils <i>921</i> |
| | | 35.5.2.3 NK Cells <i>921</i> |
| | | 35.5.2.4 Lymphocytes <i>921</i> |
| 35.6 | Growth | Hormone 921 |
| 55.0 | 35.6.1 | Macrophages 921 |
| | 35.6.2 | NK Cells 922 |
| | 35.6.3 | Lymphocytes 922 |
| 35.7 | | nes 922 |
| 33.7 | 35.7.1 | Leptin 923 |
| | 33.7.1 | 35.7.1.1 Macrophages 923 |
| | | 35.7.1.2 Neutrophils 923 |
| | | 35.7.1.3 NK Cells 923 |
| | | 35.7.1.4 Lymphocytes 923 |
| | 35.7.2 | Adiponectin 924 |
| | 33.7.2 | • |
| | | 35.7.2.1 Macrophages <i>924</i> 35.7.2.2 Dendritic Cells <i>924</i> |
| | | 35.7.2.3 NK Cells 924 |
| | | |
| | | 35.7.2.4 Neutrophils 924 |
| | 25.7.2 | 35.7.2.5 Lymphocytes 924 |
| | 35.7.3 | Ghrelin 925 |
| | | 35.7.3.1 Macrophages 925 |
| | | 35.7.3.2 NK Cells 925 |
| | | 35.7.3.3 Neutrophils 925 |
| | 25.5.4 | 35.7.3.4 Lymphocytes 925 |
| | 35.7.4 | Other Adipokines 926 |
| | | 35.7.4.1 Resistin 926 |
| 25.0 | 2.6.1 | 35.7.4.2 Visfatin 926 |
| 35.8 | | cortins 927 |
| | 35.8.1 | Macrophages 927 |
| | 35.8.2 | |
| | | Neutrophils 927 |
| | 35.8.4 | Lymphocytes 927 |
| 35.9 | | eptide Y 927 |
| | 35.9.1 | Macrophages 928 |
| | 35.9.2 | NK Cells 928 |
| | 35.9.3 | Neutrophils 928 |
| | 35.9.4 | Lymphocytes 928 |
| 35.10 | Orexin | 929 |
| | 35.10.1 | Macrophages 929 |
| | 35.10.2 | Neutrophils 929 |
| 35.11 | | getics + Metabolism 929 |
| | 35.11.1 | Dendritic Cells 929 |
| | 35.11.2 | Macrophages 930 |

| | 35.11.3 | Neutrophils 930 | |
|--------|--|---|--|
| | 35.11.4 | Lymphocytes 930 | |
| Refere | nces 93 | | |
| 36 | Microenvironmental Regulation of Innate Immune Cell Function | | |
| | Emily R. | Watts, Eilise Ryan, Sarah R. Walmsley, and Moira K.B. Whyte | |
| 36.1 | Introduction 947 | | |
| 36.2 | The role | e of Hypoxia in Regulating Innate Immune Cell Function 949 | |
| | 36.2.1 | Physiological Response to Hypoxia 949 | |
| | 36.2.2 | Hypoxia and Innate Immune Cell Survival 950 | |
| | 36.2.3 | Chemotaxis in Hypoxia 951 | |
| | 36.2.4 | Secretory Function in Hypoxia 952 | |
| | 36.2.5 | Phagocytosis in Hypoxia 952 | |
| | 36.2.6 | Bacterial Killing 952 | |
| | 36.2.7 | Antigen Presentation 953 | |
| 36.3 | | lism and Nutrient Availability 953 | |
| 36.4 | Impact | of Host–Pathogen Interactions on Innate Immune Cell | |
| | Functio | n 956 | |
| | 36.4.1 | Damage-associated Molecular Patterns Activate the Innate | |
| | | Immune System 956 | |
| | 36.4.2 | Pathogen Avoidance of Immune Cell Recognition 957 | |
| | 36.4.3 | Preventing Innate Immune Cell Recruitment 957 | |
| | 36.4.4 | Manipulating Phagocytosis and Antigen | |
| | | Presentation 958 | |
| | 36.4.5 | Subversion of Immune Cell Death 958 | |
| 36.5 | | natory Mediators 959 | |
| | 36.5.1 | Oxidants 959 | |
| | 36.5.2 | Cytokines and Chemokines 961 | |
| | 36.5.3 | Lipid Mediators in the Innate Immune Response 964 | |
| | 36.5.4 | Microvesicles 965 | |
| 36.6 | | | |
| Refere | nces 96 | 66 | |
| 37 | G 3500 | tics of Inflammation 971 | |
| | | achharajani and Charles E. McCall | |
| 37.1 | | tics and Homeostasis Protection 971 | |
| 37.2 | Epigene | tic Principles 972 | |
| | | 37.2.1.1 Epigenetic Language 973 | |
| 37.3 | | tics of Successful Inflammation 974 | |
| | 37.3.1 | Preepigenetic Sensing and Signaling 974 | |
| | 37.3.2 | Epigenetically Poised Enhancer–Promoter Regions 975 | |
| | 37.3.3 | Inflammation Initiation 975 | |
| | 37.3.4 | Inflammation Adaptation 976 | |
| | 37.3.5 | Inflammation Resolution and Epigenetic Memory 977 | |
| 37.4 | | etics of Unsuccessful Inflammation 978 | |
| | 37.4.1 | Acute Inflammation with Epigenetic Dysregulation 978 | |
| | 37.4.2 | Chronic Inflammation with Epigenetic Dysregulation 979 | |

| Epigene 37.5.1 37.5.2 37.5.3 | Inmunometabolism 980 Immunometabolism and Chronic Inflammation 980 Immunometabolism and Acute Inflammation 981 Distinct Differences in Immunometabolic Coupling Occur During Acute versus Chronic Inflammation 982 | |
|---|---|--|
| Sirtuins | : An Epigenetic Homeostat 983 | |
| 37.6 Sirtuins: An Epigenetic Homeostat 98337.7 Epigenetic-based Inflammation Treatment 984 | | |
| 37.7.1 | Emerging Data Support that Targeting SIRT1 Homeostat Function may Treat Unsuccessful Inflammation 984 | |
| 37.8 Summary <i>987</i> | | |
| ences 98 | 37 | |
| | | |
| | | |
| ive Infla | mmation and Diseases 993 | |
| | | |
| | and Inflammation 995 | |
| | Sokołowska, Anna Głobińska, and Cezmi A. Akdis | |
| | | |
| 38.1.1 | Overview of Mechanisms of Allergic Inflammatory | |
| | Response 996 | |
| | mmunity and Its Role in Allergic Inflammation 997 | |
| 38.2.1 | Microbial Pattern Recognition by the Innate Immune | |
| | System 997 | |
| | Epithelial Cells 998 | |
| 38.2.3 | Dendritic Cells 999 | |
| 38.2.4 | Monocytes and Macrophages 1000 | |
| 38.2.5 | Mast Cells and Basophils 1001 | |
| 38.2.6 | Eosinophils 1001 | |
| 38.2.7 | Innate Lymphoid Cells 1002 | |
| 38.2.8 | NKT Cells 1003 | |
| 38.2.9 | Natural Killer Cells 1003 | |
| 38.2.10 | Role of Microbiota in Allergic Inflammation 1003 | |
| Adaptiv | re Immunity and its Role in Allergic Inflammation 1004 | |
| 38.3.1 | Central and Peripheral Tolerance Mechanisms 1004 | |
| 38.3.2 | Antigen Recognition by T Cell 1005 | |
| 38.3.3 | T Cell Subsets 1006 | |
| | 38.3.3.1 Th1/Th2 Paradigm 1006 | |
| | 38.3.3.2 Other T-Helper Subsets 1009 | |
| | 38.3.3.3 Regulatory T (Treg) Cells 1010 | |
| 38.3.4 | B Cells and Immunoglobulins 1012 | |
| | 37.5.1 37.5.2 37.5.3 Sirtuins Epigene 37.7.1 Summa ences 98 ive Infla Allergy Milena 9 Introdu 38.1.1 Innate I 38.2.1 38.2.2 38.2.3 38.2.4 38.2.5 38.2.6 38.2.7 38.2.8 38.2.9 38.2.10 Adaptiv 38.3.1 38.3.2 38.3.3 | |

38.3.4.1 B-Cell Activation and Fate 1012

38.3.4.3 Other B-cell Functions and B-cell

38.3.4.2 Immunoglobulins 1014

Subsets 1015

Cytokines of Allergic Inflammation 1015

IL-4 1016

IL-5 1016

38.4

38.4.1

38.4.2